Search Results
Sep 30, 2025, 09:02 ET Introducing The Beauty Lab at Cohere Beauty
The facility underscores Cohere Beauty's role as a collaborative CDMO partner, highlighting its concierge-level service that empowers brands to bring top-quality products to market quickly and efficiently.
More news about: Cohere Beauty
Sep 29, 2025, 22:46 ET InnoMax MedTech Chairman Jackson Shih: Bridging Technical Gaps with End-to-End Services for Medical Device Manufacturers
rehabilitation, and wearable health devices," said Jackson Shih, Chairman of InnoMax MedTech, during a live interview on September 25. As a China-based CDMO (Contract Development and Manufacturing Organization), InnoMax MedTech provides end-to-end, precision development and manufacturing services for medical
More news about: InnoMax MedTech
Sep 29, 2025, 19:00 ET Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio
6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium Bio (ASX: CMB). Under the agreement, Cambium will entrust Locus Cell with the contract development and manufacturing (CDMO) of Elate Ocular® -related. Elate Ocular®,
More news about: Locus cell
Sep 29, 2025, 15:42 ET FAMAR Group: Dr. Riku Rautsola Appointed New CEO
Directors and an advisor to MidEuropa during the acquisition of FAMAR last year. Riku is a globally experienced leader in the pharmaceutical, biotech and CDMO industries, having held CEO and senior executive positions at several leading companies, creating sustained profitable growth Under
More news about: FAMAR Group
Sep 29, 2025, 13:29 ET FAMAR Group: Dr. Riku Rautsola Appointed New CEO
Directors and an advisor to MidEuropa during the acquisition of FAMAR last year. Riku is a globally experienced leader in the pharmaceutical, biotech and CDMO industries, having held CEO and senior executive positions at several leading companies, creating sustained profitable growth Under
More news about: FAMAR Group
Sep 28, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
third-party manufacturing vendor"—specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")—"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded."
More news about: Pomerantz LLP
Sep 25, 2025, 08:00 ET Verismo Therapeutics Announces Partnership with Miltenyi Biotec to Support Advancing Clinical Programs
today announced the successful manufacture of its first clinical cell product using lentiviral vector supplied by Miltenyi Bioindustry, a dedicated CDMO division of Miltenyi Biotec. The batch was produced for STAR-101, a Phase 1 clinical trial evaluating Verismo's lead pipeline SynKIR™-110 targeting
More news about: Verismo Therapeutics
Sep 25, 2025, 03:30 ET Evonik and AMSilk extend partnership for sustainable biotech silk materials
the life sciences industry including pharmaceutical excipients, personal care, advanced foods and nature-identical materials. With over 4,000 m³ of CDMO fermentation capacity across sites in the US and Europe, Evonik serves as a global one-stop-shop for biotech production,
More news about: AMSilk
Sep 24, 2025, 11:30 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive
third-party manufacturing vendor"-specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")-"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded." On
More news about: Faruqi & Faruqi, LLP
Sep 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
third-party manufacturing vendor"—specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")—"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded." On
More news about: Pomerantz LLP
Sep 23, 2025, 08:00 ET Wisconsin's Nuclear Medicine Corridor Accelerates Cancer Treatment Breakthroughs
producers of non-carrier added actinium-225 (n.c.a. Ac-225). The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance
More news about: SHINE Technologies, LLC
Sep 18, 2025, 18:53 ET Faruqi & Faruqi Reminds Unicycive Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 - UNCY
third-party manufacturing vendor"-specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")-"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded." On
More news about: Faruqi & Faruqi, LLP
Sep 18, 2025, 11:57 ET Mikart and Nano PharmaSolutions Announce Positive Interim Data from NT-301 Phase 1 Trial and Expansion of NanoTransformer® Manufacturing Capabilities
Sept. 18, 2025 /PRNewswire/ -- Mikart, LLC, a leading contract development and manufacturing organization (CDMO), and Nano PharmaSolutions, Inc. (NPS), a nanodrug delivery pharmaceutical company, today announced positive safety and pharmacokinetics data from the
More news about: Mikart, LLC
Sep 18, 2025, 10:01 ET Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Surges to USD 60.3 Billion by 2033, Propelled by 7.3% CAGR - Verified Market Reports®
becoming a commercial differentiator for procurement teams assessing CDMO partners on both cost and ESG metrics.Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Executive analysis The CDMO outsourcing market now represents a strategic lever for pharmaceutical
More news about: Verified Market Reports
Sep 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
third-party manufacturing vendor"—specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")—"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded." On
More news about: Pomerantz LLP
Sep 18, 2025, 10:00 ET UPSHER-SMITH ADDS DIFLUPREDNATE OPHTHALMIC EMULSION TO ITS GENERICS PORTFOLIO
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Upsher-Smith Laboratories, LLC
Sep 17, 2025, 12:08 ET Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101
Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), today announced it has entered into an agreement with MindImmune Therapeutics, a biopharmaceutical company focused on neuroinflammation and Alzheimer's
More news about: Wheeler Bio, Inc.
Sep 17, 2025, 09:43 ET Piramal Pharma Solutions aumenta le capacità di formulazione con l'aggiunta della nuova pressa per compresse bi-strato Korsch XM-12 presso il suo stabilimento di Morpeth, Regno Unito
17 settembre 2025 /PRNewswire/ -- Piramal Pharma Solutions, un'organizzazione leader mondiale nello sviluppo e nella produzione a contratto (CDMO) e parte di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), è lieta di annunciare la recente acquisizione di una pressa all'avanguardia per compresse
More news about: Piramal Pharma Solutions
Sep 17, 2025, 09:38 ET Piramal Pharma Solutions erweitert seine Formulierungskapazitäten mit einer neuen Korsch XM-12 Zweischichttablettenpresse im Werk Morpeth, UK
September 2025 /PRNewswire/ -- Piramal Pharma Solutions, ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO) und Teil von Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), freut sich, die kürzlich erfolgte Anschaffung einer hochmodernen Korsch XM-12 Presse
More news about: Piramal Pharma Solutions
Sep 17, 2025, 09:31 ET Piramal Pharma Solutions augmente ses capacités de formulation avec l'ajout d'une nouvelle presse à comprimés bicouches Korsch XM-12 sur son site de Morpeth, au Royaume-Uni.
17 septembre 2025 /PRNewswire/ -- Piramal Pharma Solutions, organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, qui fait partie intégrante de Piramal Pharma Ltd. (NSE : PPLPHARMA) (BSE : 543635), a le plaisir d'annoncer l'acquisition récente
More news about: Piramal Pharma Solutions
Sep 17, 2025, 00:58 ET PPS aumenta sus capacidades de formulación con la nueva prensa de comprimidos bicapa Korsch XM-12
17 de septiembre de 2025 /PRNewswire/ -- Piramal Pharma Solutions, organización líder mundial en desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), se complace en anunciar la reciente adquisición de una prensa de comprimidos bicapa
More news about: Piramal Pharma Solutions
Sep 16, 2025, 10:01 ET Medical Device OEM/ODM/CDMO Industry Forecast: CAGR of 7.5% to 2031 Amid Growing Healthcare Innovation | Valuates Reports
device OEM/ODM/CDMO market? OEMODMCDMOWhat are the main applications of the Medical device OEM/ODM/CDMO market? EquipmentConsumablesKey Players in the Medical device OEM/ODM/CDMO market:
More news about: Valuates Reports
Sep 16, 2025, 07:33 ET Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
Sept. 16, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is excited to announce its recent acquisition of a state-of-the-art Korsch XM-12 bilayer
More news about: Piramal Pharma Solutions
Sep 16, 2025, 07:25 ET Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
Sept. 16, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), is excited to announce its recent acquisition of a state-of-the-art Korsch XM-12 bilayer
More news about: Piramal Pharma Solutions
Sep 15, 2025, 10:01 ET Made Scientific and Basilard BioTech Announce Technology Partnership to Advance Ex Vivo Gene Delivery for T Cell and iPSC Therapies
organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical-and-commercial supply. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the agility and entrepreneurial spirit of a specialist CDMO with
More news about: Made Scientific, Inc.